BR0207487A - Método de tratamento de tumores em mamìferos e uso de compostos de epotilona - Google Patents

Método de tratamento de tumores em mamìferos e uso de compostos de epotilona

Info

Publication number
BR0207487A
BR0207487A BR0207487-7A BR0207487A BR0207487A BR 0207487 A BR0207487 A BR 0207487A BR 0207487 A BR0207487 A BR 0207487A BR 0207487 A BR0207487 A BR 0207487A
Authority
BR
Brazil
Prior art keywords
mammals
treatment
present
tumors
treating tumors
Prior art date
Application number
BR0207487-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Francis Y F Lee
Original Assignee
Brystol Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23028846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0207487(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brystol Myers Squibb Company filed Critical Brystol Myers Squibb Company
Publication of BR0207487A publication Critical patent/BR0207487A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0207487-7A 2001-02-20 2002-02-06 Método de tratamento de tumores em mamìferos e uso de compostos de epotilona BR0207487A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26983601P 2001-02-20 2001-02-20
PCT/US2002/004255 WO2002066038A1 (en) 2001-02-20 2002-02-06 Treatment of refractory tumors using epothilone derivatives

Publications (1)

Publication Number Publication Date
BR0207487A true BR0207487A (pt) 2004-08-10

Family

ID=23028846

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207487-7A BR0207487A (pt) 2001-02-20 2002-02-06 Método de tratamento de tumores em mamìferos e uso de compostos de epotilona

Country Status (18)

Country Link
US (2) US6686380B2 (enExample)
EP (1) EP1385529A4 (enExample)
JP (1) JP2004522774A (enExample)
KR (1) KR20040025895A (enExample)
CN (1) CN1774253A (enExample)
BG (1) BG108075A (enExample)
BR (1) BR0207487A (enExample)
CA (1) CA2438610A1 (enExample)
EE (1) EE200300396A (enExample)
HU (1) HUP0303175A2 (enExample)
IL (1) IL156988A0 (enExample)
IS (1) IS6918A (enExample)
MX (1) MXPA03007394A (enExample)
NO (1) NO20033684L (enExample)
PL (1) PL363362A1 (enExample)
RU (1) RU2003128311A (enExample)
WO (1) WO2002066038A1 (enExample)
ZA (1) ZA200306173B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
RU2003126171A (ru) * 2001-01-25 2005-02-27 Бристол-Маерс Сквибб Компани (Us) Парентеральный состав, содержащий аналоги эпотилона
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004018478A2 (en) * 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
JP2006504743A (ja) 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
TW200503738A (en) * 2003-07-16 2005-02-01 Tzu Chi Buddhist General Hospital Method for extracting antineoplastic components from bupleurum scorzonerifolium
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
WO2006017761A2 (en) * 2004-08-05 2006-02-16 Emory University Epothilone analogues as therapeutic agents
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
BRPI0518286A2 (pt) * 2004-11-18 2008-11-11 Bristol Myers Squibb Co microesfera com revestimento entÉrico contendo ixabepilona e sua preparaÇço
EP1856255A4 (en) 2005-02-11 2010-01-27 Univ Southern California PROCESS FOR EXPRESSING PROTEINS VIA DISULPHIDE BRIDGES
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
BR112022013685A2 (pt) 2020-01-10 2022-09-06 R Pharm Us Operating Llc Composições de ixabepilona

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2198752A1 (en) * 1994-08-31 1996-03-07 Jason Scott Sawyer Methods for identifying and treating resistant tumors
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
PL193229B1 (pl) 1996-11-18 2007-01-31 F Biotechnologische Forschung Epotylon C, epotylon D, epotylon E i epotylon F, sposób biotransformacji epotylonu A, sposób biotransformacji epotylonu B oraz środek leczniczy
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
WO1998038192A1 (de) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
ATE224316T1 (de) 1997-03-06 2002-10-15 Harry Nijenhuis Man B V Umschlageinrichtung für container und ein eisenbahnwagen
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (de) 1997-04-18 2002-10-09 Studiengesellschaft Kohle mbH Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2184307T3 (es) 1997-07-16 2003-04-01 Schering Ag Derivados de tiazol, procedimiento para su preparacion y su utilizacion.
JP2001512723A (ja) 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用
US6982142B2 (en) * 1997-12-01 2006-01-03 John Wayne Cancer Institute Methods for screening therapeutically effective agents
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
HUP0101564A3 (en) 1998-02-05 2002-06-28 Novartis Ag Compositions containing epothilone
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
AU2795000A (en) 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
AU3156700A (en) 1999-02-18 2000-09-04 Schering Aktiengesellschaft 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
SK287200B6 (sk) 1999-02-22 2010-03-08 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
FR2793288B1 (fr) 1999-05-06 2001-07-20 Transrol Rotule permettant la transmission d'un couple
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
RU2003126171A (ru) 2001-01-25 2005-02-27 Бристол-Маерс Сквибб Компани (Us) Парентеральный состав, содержащий аналоги эпотилона
EE05301B1 (et) 2001-01-25 2010-06-15 Bristol-Myers Squibb Company Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
RS20050235A (sr) 2002-09-23 2007-06-04 Bristol Myers Squibb Company, Postupci za pripremanje,izolaciju i prečišćavanje epotilona b i kristalne strukture epotilona b dobijene primenom x-zraka
US7460891B2 (en) 2002-10-21 2008-12-02 Microsoft Corporation Method and system to shut down and control computer radios

Also Published As

Publication number Publication date
WO2002066038A1 (en) 2002-08-29
KR20040025895A (ko) 2004-03-26
US20020165258A1 (en) 2002-11-07
USRE41393E1 (en) 2010-06-22
EP1385529A4 (en) 2007-05-09
BG108075A (bg) 2005-04-30
ZA200306173B (en) 2004-11-23
PL363362A1 (en) 2004-11-15
CA2438610A1 (en) 2002-08-29
US6686380B2 (en) 2004-02-03
NO20033684L (no) 2003-10-13
JP2004522774A (ja) 2004-07-29
RU2003128311A (ru) 2005-03-10
MXPA03007394A (es) 2003-12-04
EE200300396A (et) 2003-12-15
HUP0303175A2 (hu) 2003-12-29
IL156988A0 (en) 2004-02-08
CN1774253A (zh) 2006-05-17
EP1385529A1 (en) 2004-02-04
NO20033684D0 (no) 2003-08-19
IS6918A (is) 2003-08-18

Similar Documents

Publication Publication Date Title
BR0207487A (pt) Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
CY1105349T1 (el) Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
BG101118A (en) Therapeutical compounds
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
BR0208373A (pt) Inibidores da tirosina cinase
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
DE60314633D1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
BR0208142A (pt) Combinações compreendendo um agente antidiarréico e epotilona ou derivado de epotilona
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR9713147A (pt) Benzamidoaldeìdo, uso do mesmo, benzamida, e, preparação medicamentosa para administração oral, parenteral ou intraperitoneal.
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR9709942A (pt) Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo
WO1999063978A3 (en) Methods of treating microbial infection and therapeutic formulations therefor
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
EP0932613A4 (en) EXPRESSION BLOCKING OF VIRULENT FACTORS IN S. AUREUS
BR0113590A (pt) 7-oxo-piridopirimidinas
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]